319 results about "Oncolytic virus" patented technology

Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

A recombinant interleukin-27 (IL27) expressing virus is described. The recombinant IL27 expressing virus comprises an oncolytic virus comprising one or more exogenous nucleic acid sequences capable of expressing in IL27 protein or a biologically active portion thereof, the exogenous nucleic acid sequences being operably linked to an expression control sequence. Methods of treating cancer by in a subject by contacting a cancer cell of the subject with a recombinant IL27 expressing virus are also described.

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.

The invention provides a recombinant oncolytic virus for treating solid tumors with rare and rare gene mutations, which is an OAV treatment platform subjected to triple virus structural protein gene modification and triple adenovirus serotype chimerism, and is named as NeoViron. NeoViron can directly deliver tumor neoantigens to a plurality of solid tumors, especially tumors with rare mutations, and a new general strategy is provided for treating a plurality of intractable tumors.

The invention relates to the technical field of biological medicines, in particular to a recombinant oncolytic virus for expressing a bispecific or trispecific single-chain antibody and application of the recombinant oncolytic virus. The recombinant oncolytic virus comprises an antibody gene integrated into a virus skeleton of the recombinant oncolytic virus; the antibody gene comprises a target antibody gene targeting tumor cells and at least one antibody gene targeting immune cells. When the antibody gene comprises a target antibody gene targeting tumor cells and an antibody gene targeting immune cells, the antibody gene is a bispecific antibody; when the antibody gene comprises a target antibody gene targeting tumor cells and two antibody genes targeting immune cells, the antibody gene is a trispecific antibody. According to the present invention, the coding gene having the bispecific single-chain antibody or the trispecific single-chain antibody is integrated in the modified oncolytic virus, such that the gene of the bispecific single-chain antibody or the trispecific single-chain antibody can be expressed in vivo so as to further improve the tumor cell treatment effect.

The present invention provides an oncolytic virus vector containing a sequence encoding IL-4 receptor targeted cargo protein, including IL-4 muteins and / or IL-13 muteins, the oncolytic virus encoded therefrom, the uses of the oncolytic virus for treating cancer.

A method for treating tumors using a combination of an oncolytic virus vaccine and immune cells. The method specifically includes the following step: treating the tumors by using a combination of the immune cells and the oncolytic virus vaccine; the oncolytic virus vaccine includes a recombinant oncolytic virus expressing a tumor antigen and is used for targeting the tumor cells; the immune cells express a chimeric antigen receptor paired with the tumor antigen, and are used for killing or destroying the tumor cells targeted; the recombinant oncolytic virus includes an M protein, G protein, N protein, P protein and L protein subjected to site-directed mutagenesis. The tumor antigen expressed by the oncolytic virus vaccine can guide the immune cells to reach the target tumor tissue center, achieving a curative effect where 1+1 is greater than 2, with a tumor cell killing rate being up to 100% at most.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

Provided are serum-resistant vaccinia extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and modified EEVs for systemic oncolytic viral therapy. Provided herein are methods to modify vaccinia viruses to produce serum resistant EEVs for systemic oncolytic viral therapy. Compositions containing serum resistant EEVs and methods of treating cancers and other proliferative diseases are provided.

The invention discloses an oncolytic virus and application of the oncolytic virus in preparation of tumor inhibition drugs. The oncolytic virus is a lentiviral vector, and the lentiviral vector comprises polynucleotide encoding p16 protein or a bioactive part of the p16 protein containing CDKN2A gene, and can effectively inhibit growth of cancer related to CDKN2A gene mutation, so that the problem that the existing oncolytic virus has biological safety risk in delivery of cancer suppressor genes is effectively solved.

The invention discloses an application of an OH2 oncolytic virus combined with a PD-1 inhibitor in preparation of an antitumor drug. The OH2 oncolytic virus and the PD-1 inhibitor are jointly applied to tumor treatment, and through the synergistic effect of the OH2 oncolytic virus and the PD-1 inhibitor, the anti-tumor immune response is enhanced, and the treatment effect is improved. According to the combined treatment scheme, tumor cells can be directly killed, recurrence and metastasis of tumors can be inhibited by activating systemic immune response, and a new treatment choice is provided for tumor patients. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the treatment effect of the anti-tumor medicine, the anti-tumor medicine can be used for evaluating the treatment effect, and the anti-tumor medicine is suitable for common tumor adaptations including colorectal cancer, esophageal cancer, head and neck tumor, gastric cancer, biliary tract system tumor, sarcoma, melanoma and other tumors.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.

The present invention is directed to an oncolytic vector together with one or more antibiotics, one or more a probiotics or other microbiome-targeting compositions, and / or one or more fecal transplant for use in the treatment of cancer. The invention is also directed to a pharmaceutical composition comprising an oncolytic vector with one or more of the following: an antibiotic, a probiotic, a microbiome-targeting composition and a fecal transplant. The invention is also directed to a kit which comprises a first container, a second container, and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing an oncolytic vector, the second container containing one of the following: an antibiotic, a probiotic, a microbiome-targeting composition or a fecal transplant, and the package insert comprises instructions for treating a subject having cancer using the compositions of the first and second containers, wherein said probiotic, microbiome-targeting composition or fecal transplant comprises or promotes a bacterial species which improves the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject, and wherein said antibiotic is effective against a bacterial species which decreases the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject.

Disclosed herein are compositions that block entry of enveloped viruses into cells, polynucleotides encoding the same, pharmaceutical compositions, and methods of treating viral infections in subjects using the disclosed compositions. Also disclosed are compositions that make a cell susceptible to viral infection, polynucleotides encoding the same and methods of making a cell susceptible to viral infection, methods of targeting an oncolytic virus to a cell, and methods of inducing cell-cell fusion.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and construction and application of the recombinant oncolytic virus. The virus takes a wild poxvirus genome as a skeleton, thymokinase TK genes are deleted through homologous recombination, and a poxvirus P-se / l promoter is used for promoting expression of a CD19 membrane localization antibody. The constructed recombinant oncopoxvirus aCD19-TM-OVV can improve the infection efficiency and gene delivery efficiency on B lymphoma in a CD19 antigen target-dependent manner, promote virus replication of the oncopoxvirus in CD19 positive B lymphoma cells, and significantly enhance the tumor growth inhibition effect on the CD19 positive B lymphoma cells in vitro and in mouse B lymphoma models.

The invention provides a novel recombinant orf virus, the recombinant orf virus expresses interleukin 15, the recombinant orf virus is an ORFV (Open Reading Frame Virus) ORFs 005-008 gene deleted strain (marked as ORFV delta), and the IL15 gene expressed by the recombinant orf virus is one of a mouse source, a human source, a cat source or a dog source. According to the invention, an ORFV oncolytic virus is used as a carrier to develop a tumor immunotherapy drug ORFVdelta-IL15 expressing IL15, and the IL15 is expressed in tumor cells by using the characteristics of virus infection, so that the activation of NK cells and T cells in a tumor microenvironment is promoted while the tumor cells are cracked, and the anti-tumor effect of the oncolytic virus is enhanced. The invention provides a new strategy for tumor treatment.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

Provided is a use of an oncolytic virus in the treatment of pain, especially in the treatment of cancer while relieving cancer pain. The drug effect time of the oncolytic virus for relieving cancer pain is obviously longer than that of the existing opioid analgesic, and the dual effects of treating cancer and easing pain are achieved at the same time.

This application relates to the biomedical technology field, and more specifically to a tumor therapy method combining recombinant oncolytic viruses and small molecule anticancer drugs. Specifically, it includes the step of treating a tumor using recombinant oncolytic viruses and small molecule anticancer drugs in combination, wherein the small molecule anticancer drugs include ALK-targeting small molecule anticancer drugs, BTK-targeting small molecule anticancer drugs, EGFR-targeting small molecule anticancer drugs, FGFR-targeting small molecule anticancer drugs, HER2-targeting small molecule anticancer drugs, Parp-targeting small molecule anticancer drugs, PI3K-targeting small molecule anticancer drugs, VEGFR-targeting small molecule anticancer drugs, CDK4 / 6-targeting small molecule anticancer drugs, and KRAS-targeting small molecule anticancer drugs, and the recombinant oncolytic viruses include site-directed mutagenesis of M protein, G protein, N protein, P protein, and L protein. In this application, it is possible to achieve an effect greater than 1+1 by using recombinant oncolytic viruses and low-molecular-weight anticancer drugs in combination to attack and kill tumor cells.

The invention relates to the technical field of biological medicine, and particularly discloses an oncolytic virus and application thereof. The oncolytic virus comprises an M protein, and compared with an amino acid sequence shown in SEQ ID NO 1, amino acid substitution of the M protein is selected from any one of a substitution group provided by the invention; the invention also relates to an expression vector of the oncolytic virus, a virus producing cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus. The invention also discloses a preparation method and application of the oncolytic virus, the oncolytic virus expression vector, the virus producing cell and / or the pharmaceutical composition. The safety and the cure rate of the oncolytic virus can be effectively improved.

The invention provides a novel recombinant orf virus (ORFV), the recombinant orf virus expresses a chemotactic factor CXC ligand 9, the recombinant orf virus is a strain ORFV [delta] 005-008 (expressed by ORFV [delta]) with ORFV ORFs 005-008 gene deletion, and the Cxc19 gene expressed by the recombinant orf virus is one of a mouse source, a human source and a cat source. The ORFV oncolytic virus is used as a carrier to develop a tumor immunotherapy drug ORFVdelta-Cxc19 expressing CXCL9, the CXCL9 is expressed in tumor cells by using the characteristics of virus infection, the collection of T cells in a tumor microenvironment is promoted while the tumor cells are cracked, and the anti-tumor effect of the oncolytic virus is enhanced. The invention provides a new strategy for tumor treatment.

The invention discloses an efficient oncolytic virus as well as a composition and application thereof, specifically, the composition comprises an oncolytic virus and an immunoregulatory factor, and the immunoregulatory factor comprises CXCL16. The composition disclosed by the invention shows a better treatment effect in a tumor model, and can induce stronger anti-tumor immune response.

Provided herein are oncolytic viruses containing payload genes, including genes encoding IL-12, FLT3L, CD40 agonists, and / or CTLA-4 antibodies. Expression cassettes, pharmaceutical compositions, and methods of treatment using these viruses are also provided. Additionally, expression cassettes and CD40 agonist molecules are also provided in the present disclosure.

The invention relates to the technical field of biological medicine, and particularly discloses an oncolytic virus and application thereof. The oncolytic virus comprises an M protein, and compared with an amino acid sequence shown in SEQ ID NO 1, amino acid substitution of the M protein is selected from any one of a substitution group provided by the invention; the invention also relates to an expression vector of the oncolytic virus, a virus producing cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus. The invention also discloses a preparation method and application of the oncolytic virus, the oncolytic virus expression vector, the virus producing cell and / or the pharmaceutical composition. The safety and the cure rate of the oncolytic virus can be effectively improved.

This disclosure relates to methods for selecting therapy for a subject with glioma, and treating said subject, according to the pretreatment tumor microenvironment, wherein when a tumor from the subject has a high level of similarity with reference samples with low tumor microenvironment, medium tumor microenvironment, or high tumor microenvironment, different therapies are selected, which can comprise an oncolytic virus, a combination of an oncolytic virus and an anti-PD-1 antibody, or a combination of an oncolytic virus, an anti-PD-1 antibody, and at least one additional immune checkpoint inhibitor, respectively.